BioNTech (NASDAQ:BNTX - Get Free Report) was upgraded by research analysts at Evercore ISI from an "in-line" rating to an "outperform" rating in a report released on Tuesday, Marketbeat Ratings reports. The brokerage presently has a $125.00 price target on the stock, up from their prior price target of $110.00. Evercore ISI's target price points to a potential upside of 22.71% from the stock's previous close.
Other equities analysts have also recently issued research reports about the stock. HSBC lifted their target price on shares of BioNTech from $97.00 to $136.00 and gave the stock a "buy" rating in a research report on Monday, October 7th. Jefferies Financial Group upgraded BioNTech from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $96.00 to $150.00 in a report on Tuesday, September 17th. HC Wainwright restated a "buy" rating and set a $150.00 target price on shares of BioNTech in a report on Monday. TD Cowen dropped their price target on shares of BioNTech from $132.00 to $122.00 and set a "hold" rating for the company in a research report on Tuesday, November 5th. Finally, UBS Group boosted their price objective on shares of BioNTech from $97.00 to $131.00 and gave the company a "neutral" rating in a research report on Wednesday, September 18th. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, BioNTech presently has a consensus rating of "Moderate Buy" and an average price target of $138.79.
Read Our Latest Analysis on BioNTech
Shares of NASDAQ BNTX opened at $101.87 on Tuesday. The business has a 50-day moving average of $113.57 and a 200-day moving average of $97.36. The firm has a market capitalization of $24.42 billion, a price-to-earnings ratio of -48.51 and a beta of 0.26. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49.
BioNTech (NASDAQ:BNTX - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $2.07. The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech's revenue for the quarter was up 38.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.73 earnings per share. Sell-side analysts expect that BioNTech will post -3.68 earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the company. FMR LLC boosted its position in shares of BioNTech by 797.8% during the third quarter. FMR LLC now owns 6,299,929 shares of the company's stock valued at $748,243,000 after purchasing an additional 5,598,190 shares in the last quarter. Fred Alger Management LLC purchased a new position in BioNTech during the third quarter valued at $59,485,000. Candriam S.C.A. boosted its holdings in shares of BioNTech by 261.2% during the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company's stock valued at $46,526,000 after buying an additional 418,695 shares in the last quarter. Point72 Asset Management L.P. grew its position in shares of BioNTech by 283.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company's stock worth $37,103,000 after buying an additional 341,311 shares during the period. Finally, Braidwell LP bought a new position in shares of BioNTech in the 3rd quarter worth about $29,425,000. Institutional investors own 15.52% of the company's stock.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.